Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Radiopharm Theranostics Limited ( (AU:RAD) ) has provided an update.
Radiopharm Theranostics Limited has received a research and development tax refund totaling A$4.5 million for the 2024 financial year from the Australian Government’s R&D tax incentive. This funding will support the continued development of its portfolio of radiopharmaceutical products for diagnostic and therapeutic applications, enhancing its position in the oncology sector and providing financial stability for ongoing projects.
The most recent analyst rating on (AU:RAD) stock is a Buy with a A$0.07 price target. To see the full list of analyst forecasts on Radiopharm Theranostics Limited stock, see the AU:RAD Stock Forecast page.
More about Radiopharm Theranostics Limited
Radiopharm Theranostics Limited is a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for areas of high unmet medical need. The company is listed on the ASX and NASDAQ and has a pipeline of distinct and highly differentiated platform technologies spanning peptides, small molecules, and monoclonal antibodies for use in cancer. Their clinical program includes one Phase 2 and three Phase 1 trials in various solid tumor cancers including lung, breast, and brain.
Average Trading Volume: 2,214,691
Technical Sentiment Signal: Sell
Current Market Cap: A$52.03M
For an in-depth examination of RAD stock, go to TipRanks’ Overview page.